Dr. Tap on Olaratumab/Doxorubicin Combination in Soft Tissue Sarcomas

Video

William Tap, MD, Medical Oncologist, Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center discusses the benefits of a olaratumab and doxorubicin combination treatment for advanced soft tissue sarcomas.

William Tap, MD, Medical Oncologist, Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center discusses the benefits of a olaratumab and doxorubicin combination treatment for advanced soft tissue sarcomas.

Soft tissue sarcomas are a rare and heterogeneous group of malignancies where there have not been tremendous advances, says Tap. In a randomized phase Ib/II study olaratumab, a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, was evaluated with or without doxorubicin. The results were significant, says Tap, with the combination showing a 10-month improvement in overall survival compared to doxorubicin alone in soft tissue sarcoma patients.

Based on these results, olaratumab received breakthrough designation status from the FDA and a large phase III study will now be conducted, says Tap.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD